SLC2A3 and non-small cell lung carcinoma: Increased GLUT-3 levels are a potential indicator of a poor prognosis and a biomarker for lower tumor differentiation in Stage I non-small cell lung cancer patients, highlighting the significance of GLUT-3 for early diagnosis and prognostic accuracy (Younes et al., 1997b; Maki et al., 2013).